Market Closed -
OTC Markets
10:24:58 09/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.0008
USD
|
+300.00%
|
|
+300.00%
|
-99.83%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
6.596
|
19.34
|
29.13
|
63.92
|
43.22
|
29.96
|
Enterprise Value (EV)
1 |
8.546
|
22.09
|
31.8
|
68.58
|
49.62
|
37.65
|
P/E ratio
|
-2.18
x
|
-8.04
x
|
-5.97
x
|
-10.7
x
|
-6.58
x
|
-4.68
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-3.73
x
|
-11
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-4.53
x
|
-12.2
x
|
-39.4
x
|
-44.2
x
|
-22.8
x
|
-28.2
x
|
FCF Yield
|
-22.1%
|
-8.17%
|
-2.54%
|
-2.26%
|
-4.38%
|
-3.55%
|
Price to Book
|
-1.5
x
|
-3.97
x
|
-5.19
x
|
-8.19
x
|
-4.48
x
|
-2.43
x
|
Nbr of stocks (in thousands)
|
24,429
|
25,781
|
26,479
|
31,960
|
33,752
|
35,252
|
Reference price
2 |
0.2700
|
0.7500
|
1.100
|
2.000
|
1.280
|
0.8500
|
Announcement Date
|
25/07/18
|
01/04/19
|
30/03/20
|
15/04/21
|
15/04/22
|
08/08/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-2.292
|
-2.006
|
-
|
-
|
-
|
-
|
EBIT
1 |
-2.293
|
-2.006
|
-3.805
|
-3.638
|
-4.019
|
-4.175
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-3.083
|
-2.117
|
-4.475
|
-4.56
|
-5.472
|
-5.168
|
Net income
1 |
-3.083
|
-2.117
|
-4.475
|
-4.56
|
-5.472
|
-5.168
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.1241
|
-0.0932
|
-0.1842
|
-0.1869
|
-0.1946
|
-0.1816
|
Free Cash Flow
1 |
-1.887
|
-1.804
|
-0.8061
|
-1.552
|
-2.176
|
-1.336
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/07/18
|
01/04/19
|
30/03/20
|
15/04/21
|
15/04/22
|
08/08/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
1.95
|
2.75
|
2.67
|
4.66
|
6.4
|
7.68
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.8507
x
|
-1.373
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.89
|
-1.8
|
-0.81
|
-1.55
|
-2.18
|
-1.34
|
ROE (net income / shareholders' equity)
|
57.1%
|
44.7%
|
84%
|
66.6%
|
61.6%
|
46%
|
ROA (Net income/ Total Assets)
|
-386%
|
-420%
|
-2,634%
|
-802%
|
-656%
|
-721%
|
Assets
1 |
0.7989
|
0.5045
|
0.1699
|
0.5687
|
0.8346
|
0.7165
|
Book Value Per Share
2 |
-0.1800
|
-0.1900
|
-0.2100
|
-0.2400
|
-0.2900
|
-0.3500
|
Cash Flow per Share
2 |
0.0100
|
0
|
0
|
0.0100
|
0
|
0.0100
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/07/18
|
01/04/19
|
30/03/20
|
15/04/21
|
15/04/22
|
08/08/23
|
|
1st Jan change
|
Capi.
|
---|
| -99.83% | 32.82K | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|